09:35 AM EST - Microbix Biosystems Inc. : Announced U.S. availability of its SARS-CoV-2 quality assessment products (QAPs™) – FDA registration enabling immediate usage by U.S. clinical laboratories to evaluate performance, procedures, and workflow of tests that detect SARS-CoV-2 virus, the causative agent of COVID-19 disease. Microbix Biosystems Inc.
shares T.MBX are trading unchanged at $0.34.
